These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 17599771)

  • 1. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.
    Shand L; Lunt M; Nihtyanova S; Hoseini M; Silman A; Black CM; Denton CP
    Arthritis Rheum; 2007 Jul; 56(7):2422-31. PubMed ID: 17599771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
    Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
    Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register.
    Hanitsch LG; Burmester GR; Witt C; Hunzelmann N; Genth E; Krieg T; Lehmacher W; Melchers I; Meurer M; Müller-Ladner U; Schulze-Lohoff E; Becker M; Sunderkoetter C; ; Riemekasten G
    Rheumatology (Oxford); 2009 Jan; 48(1):70-3. PubMed ID: 19056798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.
    Clements PJ; Hurwitz EL; Wong WK; Seibold JR; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen VD; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Furst DE
    Arthritis Rheum; 2000 Nov; 43(11):2445-54. PubMed ID: 11083267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial.
    Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Seibold JR
    Arthritis Rheum; 2001 Mar; 44(3):653-61. PubMed ID: 11263780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
    DeMarco PJ; Weisman MH; Seibold JR; Furst DE; Wong WK; Hurwitz EL; Mayes M; White B; Wigley F; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
    Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe organ involvement in systemic sclerosis with diffuse scleroderma.
    Steen VD; Medsger TA
    Arthritis Rheum; 2000 Nov; 43(11):2437-44. PubMed ID: 11083266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.
    Denton CP; Merkel PA; Furst DE; Khanna D; Emery P; Hsu VM; Silliman N; Streisand J; Powell J; Akesson A; Coppock J; Hoogen Fv; Herrick A; Mayes MD; Veale D; Haas J; Ledbetter S; Korn JH; Black CM; Seibold JR; ;
    Arthritis Rheum; 2007 Jan; 56(1):323-33. PubMed ID: 17195236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of morbidity and mortality of systemic sclerosis in Canada.
    Al-Dhaher FF; Pope JE; Ouimet JM
    Semin Arthritis Rheum; 2010 Feb; 39(4):269-77. PubMed ID: 18706680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A longitudinal follow-up of hand involvement and activities of daily living in early systemic sclerosis.
    Sandqvist G; Hesselstrand R; Eberhardt K
    Scand J Rheumatol; 2009; 38(4):304-10. PubMed ID: 19296402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.
    Matsushita T; Hasegawa M; Hamaguchi Y; Takehara K; Sato S
    J Rheumatol; 2006 Feb; 33(2):275-84. PubMed ID: 16465658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial.
    Mayes MD; O'Donnell D; Rothfield NF; Csuka ME
    Arthritis Rheum; 2004 Feb; 50(2):553-7. PubMed ID: 14872498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.
    Clements PJ; Furst DE; Wong WK; Mayes M; White B; Wigley F; Weisman MH; Barr W; Moreland LW; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold JR
    Arthritis Rheum; 1999 Jun; 42(6):1194-203. PubMed ID: 10366112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
    Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
    Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis.
    Herrick AL; Lunt M; Whidby N; Ennis H; Silman A; McHugh N; Denton CP
    J Rheumatol; 2010 Jan; 37(1):116-24. PubMed ID: 19955050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.
    Wu W; Jordan S; Graf N; de Oliveira Pena J; Curram J; Allanore Y; Matucci-Cerinic M; Pope JE; Denton CP; Khanna D; Distler O;
    Ann Rheum Dis; 2019 May; 78(5):648-656. PubMed ID: 30852552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.
    Maurer B; Graf N; Michel BA; Müller-Ladner U; Czirják L; Denton CP; Tyndall A; Metzig C; Lanius V; Khanna D; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1124-31. PubMed ID: 24981642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.
    Denton CP; Engelhart M; Tvede N; Wilson H; Khan K; Shiwen X; Carreira PE; Diaz Gonzalez F; Black CM; van den Hoogen FH
    Ann Rheum Dis; 2009 Sep; 68(9):1433-9. PubMed ID: 18782794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.